122 results about "Anti atherosclerotic" patented technology

A method of assessing the likelihood that a person who is asymptomatic for coronary artery disease does in fact have the disease is disclosed. The levels of an atherogenic protein and acute phase reactant and optionally of anti-atherogenic protein for an individual are obtained and compared to one or more cut-points related to those substances and, based on the comparison(s), an assessment is made of the likelihood that the individual has coronary artery disease. The atherogenic protein may be OxLDL, the acute phase reactant may be C-reactive protein or fibrinogen, and the anti-atherogenic protein may be HDL.

The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.

A peptide for diagnosing, preventing and treating atherosclerosis, and a use thereof, comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and a use thereof. The peptide effectively targets atherosclerotic plaques, and binds to IL-4R to thereby exhibit antagonistic effects on IL-4-mediated signaling of cellular inflammatory reaction and survival reaction. The peptide of the present invention can be used for diagnosis of atherosclerosis, prevention and treatment of IL-4-induced inflammatory reaction and prevention and treatment of atherosclerosis which is primarily caused by the inflammatory reaction, as well as for prevention or treatment of atherosclerosis via conjugation with an anti-atherosclerotic drug.

The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.

The present invention relates to a medicine composition conlaining resulvatatine or pivatatine compound and vitamins B, in which the resulvatatine or pivatatine content is 1-40 mg and vitamins B content is 0.1-50 mg. Said invention also provides the application of said medicine composition in preparation of medicine for preventing and curing the diseases of atherosclerosis, angiocardiopathy and cerebrovascular disease.

The invention relates to the field of pharmacy, and specifically relates to the preparation and application of a drug. The drug is prepared from triterpene compounds, which are purchased or extracted from cyclocarya paliurus, and is used to inhibit the synthesis and secretion of apoB48 in the intestinal tracts. The invention especially discloses applications of triterpene compounds in the preparation of drugs for preventing hyperlipidemia, cardiovascular and cerebrovascular diseases, and atherosis. The invention further discloses a series of triterpene compounds and the preparation and applications thereof in the preparation of drugs for inhibiting the synthesis and secretion of apoB48 in intestinal tracts.

The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg/kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.

The invention discloses a preparation method of pH-sensitive hyaluronic acid nano drug-loading particles targeting atherosclerosis, and belongs to the technical field of new drug preparations. The preparation method comprises the following steps: 1) covalent bonding of a bridging agent having terminal hydrazine groups to hyaluronic acid is carried out to obtain a hyaluronic acid derivative; 2) analdehyde compound containing a hydrophobic chain is grafted to the hyaluronic acid derivative through a terminal hydrazine group to obtain a pH-sensitive hyaluronic acid copolymer containing a hydrazone bond; and 3) a hydrophobic anti-atherosclerosis drug is encapsulated into the hydrophobic core of the pH-sensitive hyaluronic acid copolymer. The invention also discloses pharmaceutical particles thereof. Biodegradable and biocompatible materials are used in the invention, and are metabolized and excreted through normal physiological pathways. The vector has multi-targeting property. By specific binding of Hyaluronic acid to CD44 and Stabilin-2 receptors overexpressed on the atherosclerotic plaque cell surface, the carrier can respond to an acidic inflammatory environment to release the drug and achieve the combined treatment of anti-oxidant drugs and anti-atherosclerosis drugs.

The invention provides a miRNA-155 used to prepare an antiatherosclerotic medicine. Trough experiments, it is proved in the invention that miRNA-155 has a substantial inhibition effect towards atherosclerotic inflammation no matter on the external cell level or on the internal atherosclerotic module mice level. Because miRNA-155 is a regulation and control molecule in the upstream of genes and simultaneously possesses a plurality of biology functions, so it is very likely that miRNA-155 can become a brand new target point of atherosclerotic treatment. The medicine provided in the invention can effectively prevent nucleic acid from being degraded in organisms, efficiently take an effect on a target organism and can be prepared into compound preparations with other known drugs treating atherosclerotic inflammation such as statins fat-adjusting drug and the like.

The invention discloses application of an extract of a traditional Chinese medicine penthorum chinense pursh in preparation of drugs for alleviating Alzheimer disease. The extract plays a role by inducing autophagy, and four key compounds in the extract are disclosed. The extract of penthorum chinense pursh and the compounds thereof show an anti-atherosclerosis oxidative stress injury effect in-vivo and in-vitro experiments, have an inhibitory effect on the formation of beta-amyloid protein fibers and the expression of Tao protein which cause Alzheimer disease, and have potential application in alleviating Alzheimer disease.

The invention provides an exogenous hydrogen sulfide donor, and discloses a therapeutic action of an anethol trithione derivative used as the exogenous hydrogen sulfide donor on cardiovascular diseases. The exogenous hydrogen sulfide donor can release hydrogen sulfide, can promote the growth of an HUVEC (human umbilical vein endothelial cell) atherosclerosis cell model, has an antiatherosclerotic effect, and hopefully becomes a new target drug researched and developed by drugs with antiatherosclerotic effects.

The invention discloses an in-vitro foam cell formation model and application thereof in asymptomatic carotid atherosclerosis study. A construction method of the foam cell formation model provided bythe invention comprises the following steps: sequentially culturing, from bottom to top, smooth muscle cells, endothelial cells and mononuclear cells in a cell culture device capable of performing mechanical stretching so as to obtain a multi-cell co-culture system; treating the multi-cell co-culture system by utilizing a low density lipoprotein, applying a tension effect to induce formation of foam cells by virtue of the cell culture device capable of performing mechanical stretching, thus obtaining the foam cell formation model during early occurrence of asymptomatic carotid atherosclerosis.According to the method disclosed by the invention, consumption of an animal model can be reduced, expenditure is saved, an economic and high-efficiency in-vitro screening model is provided for carotid atherosclerosis resistant new drug screening, and the in-vitro foam cell formation model has the advantages of being simple in preparation method, convenient in experimental operation, low in timeconsumption and stable in performance.

The invention provides a ginger and garlic enteric-coated tablet and a preparation method thereof. The ginger and garlic enteric-coated tablet is prepared from ginger and garlic essence as raw materials by a beta-cyclodextrin inclusion process, has broad-spectrum antibacterial action, and also the functions of reducing blood fat and blood sugar, resisting atherosclerosis, resisting tumor, improving the organism immunity, and the like, and is high in technical content, high in inclusion rate, accurate in product drug release position, and high in bioavailability, so that the medicine is high in effective ingredient content, and strong in antibacterial action, thus overcoming the shortcomings that the previous product is low in effective ingredient content, has unpleasant odor, is inconvenient to carry and the like, and ensuring the quality of the product.

The invention discloses a furoxan NO donor-type statin derivative and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The derivative has the structural formula represented by the following formula: wherein R is an alkyl, R1 is a statin residual group, and R2 is an aryl or an aryl sulfonyl. A statin drug is selected to "hybridize" with a NO donor, both NO and the statin drug have good therapeutic effects on atherosclerosis, and the problem of the mismatch of action mechanisms of NO and the statin drug is effectively avoided. In addition, 4-coumaric acid is selected as a linking group, and thus the therapeutic effect of the drug can be effectively enhanced. The compound can effectively release NO in vitro, and the useful attempt for the development of NO donor anti-atherosclerosis drugs is made.

The invention discloses a kit for detecting anti-atherosclerosis drugs in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and belongs to the technical field of blood plasma detection. The kit aims at common anti-atherosclerosis medicines such as atorvastatin, o-hydroxy atorvastatin, p-hydroxy atorvastatin, rosuvastatin and digoxin. The kitdisclosed by the invention adopts an LC-MS/MS method, can be used for detecting the anti-atherosclerosis drugs at one time, and can be used for simultaneously monitoring a target drug and a metabolite; the kit is high in sensitivity and good in accuracy, can be well applied to clinical application, and provides a reliable basis for combined medication research of the blood plasma atherosclerosis-resistant drug.